Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cut labeling rule proposed revision limits scope of controls to labeling likely to be used by consumers.

Executive Summary

FDA CUT LABELING CONTROLS LIMITED TO LABELING LIKELY TO BE READ BY CONSUMERS under a proposed rule published in the July 29 Federal Register. The proposed rule modifies regs published in August 1993 that "applied to all types of labeling including product inserts, multiunit containers packaged in individual containers and shipping containers," the Federal Register notice says. The rule enumerates control features required if cut labeling is used. Cut labeling, also known as gang-printed labeling, is "labeling derived from a sheet of material on which more than one item of labeling is printed." FDA found that because the various labeling pieces must be cut or separated and transported, "stacks of labeling of similar size, shape and color could easily be intermixed."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030642

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel